Trial Profile
Influence of Omalizumab Co-treatment on Honey-bee Venom Immunotherapy Failure Due to Systemic Reactions
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Nov 2018
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Anaphylaxis; Hypersensitivity
- Focus Therapeutic Use
- 22 Nov 2016 New trial record